Assessment of potential treatments for drug-induced respiratory depression and overdose toxicity. Ordering period: september 26, 2022 - september 25, 2027. N01DA-22-8958.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95022D00019
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 5 $766,462 obligated
Award facts
- Opportunity
-
- Assessment of Potential Treatments to Treat Drug-induced Respiratory Depression and Overdose Toxicity Pre-Solicitation · 75N95022R00012 · Posted Sep 7, 2021
- Combined order value
- $766,462 Current and potential, with all options
- Last date to order 82% complete
- IDV ceiling 12% used
- $6,500,000.00
- Maximum order
- $6,500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this IDV
The National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) awarded a $6.5 million single-award Indefinite Delivery Contract (IDC) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization, to assess potential treatments for drug-induced respiratory depression and overdose toxicity. The contract has a period of performance from September 26, 2022 to September 25, 2027.
Under this IDC, NIDA has issued several cost-plus-fixed-fee delivery orders to Lovelace, valued at $102,721 to $211,128, for tasks such as evaluating the ability of test articles to stimulate respiration or reverse the respiratory depressant effects of opioids in rodent models. This work supports NIDA's efforts to develop medical countermeasures to address the opioid overdose crisis. Lovelace has extensive experience providing preclinical research services to federal health agencies like NIH, FDA, and BARDA across the drug development lifecycle.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N95022D00019?
75N95022D00019 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 26, 2022.
How much is contract 75N95022D00019 worth?
Orders under 75N95022D00019 have obligated $766,462. 75N95022D00019's own ceiling is $6,500,000. A single order can be worth up to $6,500,000.
How many orders have been placed under contract 75N95022D00019?
5 orders have been placed under 75N95022D00019, the latest on March 21, 2024.
Who can order from contract 75N95022D00019?
75N95022D00019 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95022D00019 competed?
The extent of competition for 75N95022D00019 was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV